Morning Trend | JW THERAP-B Oversold Seeking Bottom, Where is the Sector Rotation Window Under Pharmaceutical Divergence?
JW THERAP-B (2126.HK) faced continued market pressure yesterday, with a short-term structure showing signs of overselling and bottom-seeking. The trading volume hit a new low for the day, with funds continuously flowing out and active buying being constrained. Technical bearish signals were significantly amplified, and fund rotation within the sector was slow, with right-side funds closely monitoring key support levels below. This week, the pharmaceutical sector as a whole is facing regulatory and policy pressures, leading to a sharp decline in market risk appetite. With frequent news on volume-based procurement, the bargaining power of innovative drug companies is once again under pressure, and pharmaceutical-themed funds are maintaining low positions, creating a strong wait-and-see atmosphere. JW THERAP-B has seen no industry positives for three days, with main funds leaning towards defensive strategies, and any intraday rebounds were quickly interrupted by selling pressure. Traders are focusing on the defensive role and the potential recovery window for sector rotation; if external sentiment warms up, a technical rebound may occur. The potential risks of short-term market fluctuations cannot be ignored, and dynamic position management and monitoring of volume signals are the main operational disciplines
JW THERAP-B (2126.HK) faced continued market pressure yesterday, with a short-term structure showing signs of overselling and bottom-seeking. The trading volume hit a new low for the day, with funds continuously flowing out and active buying being restricted. Technical bearish signals were significantly amplified, and fund rotation within the sector was slow, with right-side funds closely monitoring key support levels below. This week, the pharmaceutical sector is facing overall regulatory and policy pressures, leading to a sharp decline in market risk appetite. With frequent news on volume-based procurement, the bargaining power of innovative drug companies is once again under pressure, and pharmaceutical-themed funds maintain low positions, creating a strong wait-and-see atmosphere. JW THERAP-B has seen no industry positives for three days, with main funds leaning towards defensive strategies, and any intraday rebounds were quickly interrupted by selling pressure. Traders are focusing on the defensive role and the potential recovery window for sector rotation; if external sentiment warms up, a technical rebound may occur. The potential risks of short-term market fluctuations cannot be ignored, and dynamic position management and monitoring of volume signals are the main operational disciplines
